CCL7
Chr 17C-C motif chemokine ligand 7
Also known as: FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7
This gene encodes monocyte chemotactic protein 3, a secreted chemokine which attracts macrophages during inflammation and metastasis. It is a member of the C-C subfamily of chemokines which are characterized by having two adjacent cysteine residues. The protein is an in vivo substrate of matrix metalloproteinase 2, an enzyme which degrades components of the extracellular matrix. This gene is part of a cluster of C-C chemokine family members on chromosome 17q. [provided by RefSeq, Jul 2008]
26
ClinVar variants
4
Pathogenic / LP
0.00
pLI score
-0.1
Missense Z
1.91
LOEUF
2
Active trials
Clinical Summary— CCL7
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
4 Pathogenic / Likely Pathogenic· 20 VUS of 26 total submissions
💊
Clinical Trials
2 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)
ensembl: Error: Ensembl fetch failed: 500 for https://rest.ensembl.org/lookup/symbol/homo_sapiens/CCL7?content-type=application/json&expand=1
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.91LOEUF
pLI 0.001
Z-score -0.45
OE 1.27 (0.58–1.91)
Highly tolerant — LoF variants common in population
Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.14Z-score
OE missense 1.06 (0.84–1.33)
53 obs / 50.2 exp
Tolerant to missense variation
Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.1.27 (0.58–1.91)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.06 (0.84–1.33)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.15
0≤1.21.6
LoF obs/exp: 4 / 3.1Missense obs/exp: 53 / 50.2Syn Z: -0.49
ClinVar Variant Classifications
26 submitted variants in ClinVar
Classification Summary
Pathogenic4
VUS20
Likely Benign2
4
Pathogenic
20
VUS
2
Likely Benign
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 0 | 0 | 4 | 0 | 4 |
Likely Pathogenic | 0 | 0 | 0 | 0 | 0 |
VUS | 0 | 11 | 9 | 0 | 20 |
Likely Benign | 0 | 0 | 2 | 0 | 2 |
Benign | 0 | 0 | 0 | 0 | 0 |
| Total | 0 | 11 | 15 | 0 | 26 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
CCL7 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
CHEMOKINE, CC MOTIF, LIGAND 7; CCL7
MIM #158106 · *
External Resources
Links to major genomics databases and tools
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer.
He J et al.·Nat Immunol
2025
ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion.
Zhao J et al.·Cancer Res
2025
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
Johnson ED et al.·Am J Respir Crit Care Med
2025Clinical trial
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.
Chang TT et al.·Cardiovasc Diabetol
2022Review
CCL2 is a key regulator and therapeutic target for periodontitis.
Jiang W et al.·J Clin Periodontol
2023
The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration.
Cheng JW et al.·Cytokine
2014Review
Molecular mechanism of distinct chemokine engagement and functional divergence of the human Duffy antigen receptor.
Saha S et al.·Cell
2024Functional
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy.
Weinhofer I et al.·EBioMedicine
2023
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Methylmalonic Acid, an Aging-Associated Metabolite, Accelerates Intervertebral Disc Degeneration by Inducing Disc Vascularization via the CCL7/JAK2-STAT3/VEGF Signaling Axis.
Jin Y et al.·Aging Cell
2026Open Access
Autophagy-driven CCL7+ monocyte terminal differentiation program fuels CD8+ T cell-mediated cardiac injury in Sepsis.
Sun X et al.·Int Immunopharmacol
2026
Targeting the CCL7-STAT1 axis attenuates microglial neurotoxicity and photoreceptor degeneration in retinitis pigmentosa.
Li R et al.·J Neuroinflammation
2026Open Access
Isoliquiritigenin inhibited complete Freund's adjuvant-induced chronic inflammatory pain via the CCL7/CCR2/ERK pathway in dorsal root ganglia neurons of mice.
Ren YM et al.·Int Immunopharmacol
2026
Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells.
Chen Y et al.·J Immunother Cancer
2025Open Access
Top 5 resultsSearch Europe PMC ↗
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
CCL7 playing a dominant role in recruiting early OCPs to facilitate osteolysis at metastatic site of colorectal cancer
Yang H et al.·Cell Commun Signal
2022
Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer
Ren X et al.·Cell Death Dis
2021
CC Chemokine Ligand 7 Derived from Cancer-Stimulated Macrophages Promotes Ovarian Cancer Cell Invasion
Jeong M et al.·Cancers (Basel)
2021
CCL7 chemokine is a marker but not a therapeutic target of acute kidney injury.
Casemayou A et al.·Nephron
2024
Insight into the Molecular Characteristics of Langhans Giant Cell by Combination of Laser Capture Microdissection and RNA Sequencing
Chen Y et al.·J Inflamm Res
2022
CCR2 macrophage response determines the functional outcome following cardiomyocyte transplantation
Vasudevan P et al.·Genome Med
2023Functional
Single-cell RNA sequencing identifies ZBP1-dependent mechanisms in OSCC progression
Lin X et al.·Cell Death Dis
2025Functional
CCL7 and olfactory transduction pathway activation play an important role in the formation of CaOx and CaP kidney stones
Zhang Q et al.·Front Genet
2024
Top 9 full-text resultsSearch PubTator3 ↗
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Knee Osteoarthritis
Dietary Supplementation With Blueberry in OA
ACTIVE NOT RECRUITINGNCT05784545Phase NAUniversity of ExeterStarted 2023-05-22
Blueberry powder supplementMaltodextrin supplementation
Healthy AdultsHigh AltitudeIsolation, Social
Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica
ENROLLING BY INVITATIONNCT06133530Phase NAIU University of Applied SciencesStarted 2023-09-24
Human milk oligosaccharidesMaltose
External Resources
Links to major genomics databases and tools